Auvega Labs Inc. has established a profitable portfolio of integrated wellness assets to fund advancements in alternative medicine, supplements and psychedelic pharmacology.
In 2020, AUVEGA plans to advance its pursuit of treatments underpinned by psychedelic substances through clinical trials; assembling the most compelling IP portfolio, clinical pipeline and drug development platform in the psychedelics space and Europe with a focus on Corporate Development and Finance.
- Micro-dosing LSD/Psilocybin
- Psilocybin High Dose.
- LSD High Dose.
Biosynthesis of Psilocybin
AUVEGA plans to successfully biosynthesize psilocybin within our first 3 months of conducting laboratory experiments, with the objective of achieving scaled production of pharmaceutical grade psilocybin for clinical settings.
Solution For The Opioid Crisis